Posted by Site Administrator on February 12, 2013
“This new finding sheds light on how the mutation causes these disorders, and it provides us with a marker that helps us track disease progression in patients with this disorder and potentially combat the disease,” says senior author Leonard Petrucelli, Ph.D., a molecular neuroscientist and director of the Department of Neuroscience at Mayo Clinic in Florida.
Categories: Research News, Technology, Treatments
|
Tags: ALS community, ALS medical care, ALS research, ALS research funding, ALS treatments, amyotrophic lateral sclerosis, biomarker ALS, Bob Stehlin, C9ORF72 gene, C9RANT, Department of Neuroscience at Mayo Clinic Florida, DNA sequence ALS, frontotemporal dementia, Leonard Petrucelli, Lou Gehrig's disease, Mayo Clinic, motor neuron cells, Motor Neuron Disease, National Institutes of Health, neurodegenerative disorders, neuronal death and toxicity, PALS, RASCALS Foundation, Robert A. Stehlin Campaign for ALS, St.Louis RASCALS ALS Lou Gehrig's Disease amotrophic lateral sclerosis
|
No comments
Posted by Site Administrator on January 13, 2013
CAMBRIDGE, Massachusetts, January 10, 2013 — The ALS Therapy Development Institute (ALS TDI) has entered into a new collaboration with to-BBB, a clinical stage biotechnology company focusing on enhanced drug delivery across the blood-brain barrier, to investigate potential treatments for ALS (aka Motor Neuron or Lou Gehrig’s disease).
“This partnership brings a new potential tool to [...]
Categories: Research News, Treatments
|
Tags: Aestus Therapeutics, ALS, ALS community, ALS cure, ALS diagnosis, ALS medical care, ALS research, ALS research funding, ALS TDI, ALS Therapy Development Institute, ALS treatments, amyotrophic lateral sclerosis, Biogen Idec, Bob Stehlin, Central Nervous System (CNS), G-Technology, liposomal drug delivery system, Lou Gehrig's disease, MDA and RGK Foundation, neurodegenerative disorders, PALS, Pieter Gaillard, RASCALS Foundation, Robert A. Stehlin Campaign for ALS, St.Louis RASCALS ALS Lou Gehrig's Disease amotrophic lateral sclerosis, Steve Perrin, to-BBB, UCB, world’s first nonprofit biotech institute
|
No comments